Login / Signup
Thomas Ertveldt
(T Ertveldt)
ORCID
Publication Activity (10 Years)
Years Active: 2021-2022
Publications (10 Years): 2
Top Topics
Drug Delivery
Induced Pluripotent Stem Cells
Cancer Therapy
Fluorescence Imaging
Top Venues
EJNMMI research
Molecular cancer therapeutics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Thomas Ertveldt
,
Lien De Beck
,
Kirsten De Ridder
,
Hanne Locy
,
Wout de Mey
,
Cleo Goyvaerts
,
Quentin Lecocq
,
Hannelore Ceuppens
,
Yannick De De Vlaeminck
,
Robin Maximilian Awad
,
Marleen Keyaerts
,
Nick Devoogdt
,
Matthias D'Huyvetter
,
Karine Breckpot
,
Ahmet Krasniqi
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Molecular cancer therapeutics
21 (7) (2022)
Quentin Lecocq
,
Pieterjan Debie
,
Janik Puttemans
,
Robin Maximilian Awad
,
Lien De Beck
,
Thomas Ertveldt
,
Yannick De De Vlaeminck
,
Cleo Goyvaerts
,
Geert Raes
,
Marleen Keyaerts
,
Karine Breckpot
,
Nick Devoogdt
Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer.
EJNMMI research
11 (1) (2021)